论文部分内容阅读
为研究ｐ１６蛋白在骨肉瘤发生中的作用及对预后的影响，采用免疫组化方法观察４６例骨肉瘤标本中ｐ１６的表达。结果表明，ｐ１６蛋白表达阳性率为５２．２％（２４／４６），阳性率在各组织学类型及临床分期的病例中无显著性差异。在３１例有随访资料的骨肉瘤中，ｐ１６阳性表达组１５例的术后生存期较ｐ１６阴性组为长，且差异有显著性（Ｐ＜０．０５）。提示ｐ１６基因变异可能在骨肉瘤发生中起一定作用，并影响预后
In order to study the role of p16 protein in the occurrence of osteosarcoma and its effect on prognosis, the expression of p16 in 46 specimens of osteosarcoma was observed by immunohistochemistry. The results showed that the positive rate of p16 protein expression was 52.2% (24/46), and the positive rate was not significantly different among the histological types and clinical stages. In 31 cases of osteosarcoma with follow-up data, the survival time of 15 cases with p16-positive expression group was longer than that of p16-negative group, and the difference was significant (P<0.05). Suggest that p16 gene mutation may play a role in the occurrence of osteosarcoma and affect the prognosis